- 14 March
-
At the end of the last year, Novouralsk-based Medsintez Plant turned 20 years old. Alexander Petrov, Chairman of the plant's Board of Directors, told Regions of Russia about the impressive successes that the company has achieved over the years and its ambitious plans for the future.
- 22 January
-
In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease. The preparations are available in the most convenient and familiar for patients dosage form – a disposable prefilled injection and have already been supplied to pharmacies.
- 13 December
-
Medsintez Plant LLC presented the latest biotechnological developments of pharmaceuticals at the largest international scientific and practical forum in the field of medicine and health care Russian Health Care Week — 2023 held from December 4 to December 8 in Moscow. The main purpose of the Forum is to facilitate the implementation of the national projects “Healthcare” and “Demography”, “Tourism and Hospitality Industry”, the federal project “Development of Medical Services Export”, as well as summarizing the results of the Year of Science and Technology in Medicine.
- 04 October
-
On September 27, as part of the business program of the GMP conference with international participation, Alexander Petrov, Chairman of the Board of Directors of Medsintez Plant LLC, took part in a Plenary Session on the issues of regulating the circulation of medicines in Russia and the EAEU, developing import independence, and increasing export potential. The session was attended by representatives of the Ministry of Industry and Trade of the Russian Federation, the Minister of Health of the Republic of Nicaragua, the WHO Representative in Russia, a Representative of the Serbian Ministry of Health and other Russian and foreign experts. Mr. Petrov spoke about the problems that Russian pharmaceutical companies face when entering international markets and suggested possible solutions.
- Home
- Cluster members
- Triton-Electronic Systems LTD
Triton-Electronic Systems LTD
Triton-ElectronicS was founded in 1989 It is the largest Russian developer and manufacturer of medical equipment for anesthesiology and emergency medicine. In terms of clinical performance, our devices meet the standards of world leaders, and at the same time, they are a more efficient choice in terms of cost of ownership.
Achievements of Triton ElectronicS in the field of development of medical equipment and technologies are closely connected with the name of Professor Boris Davidovich Zislin. B.D. Zislin was the chief anesthetist of the Sverdlovsk Region for 37 years. His innovative ideas have contributed to the development of innovative medical technologies and the organization of the production of a number of medical devices for anesthesiology and emergency medicine.
Triton-ElectronicS creates unique and fundamentally new solutions for the global medical equipment market. These solutions are simple, easy to use and reliable. The company creates the solutions needed by the modern consumer.
ALV devices of JV100 series for high-frequency jet ventilation and MV300 series for conventional ventilation. In addition to the standard ventilation modes, the Zisline MV300 ventilator features the iSV adaptive ventilation mode, which provides maximum patient comfort, and also allows adapting the patient to the transition to spontaneous breathing efficiently and safely – the parameters are adjusted according to respiratory monitoring data. The device also allows assessing the true metabolic needs of the patient by indirect calorimetry.
The specialized single-channel monitor MGA-06 is designed for evaluation and long-term monitoring of the anaesthetic depth and sedation level of the patient. It is used during anesthesia and sedation in the intensive care unit. The main parameter to be determined is the brain activity index (AI).
MPR6-03 patient monitors provide monitoring of 5 main parameters (Harvard Standard), as well as additional monitoring: analysis of anesthetic gases, assessment of the anaesthetic depth and sedation level, non-invasive assessment of central hemodynamic parameters, monitoring of CO2 in the forward and lateral flows, including volumetric capnometry, assessment of the true metabolic needs of the patient, respiratory mechanics, monitoring of invasive pressures, including low ones.
12/5, Sibirsky Tract, Ekaterinburg
Tel.: + (343) 304-60-50
Е-mail: mail@triton.ru
www.triton.ru
